Endonovo Therapeutics Statistics
Total Valuation
ENDV has a market cap or net worth of 120,661.
| Market Cap | 120,661 |
| Enterprise Value | n/a |
Important Dates
The last earnings date was Friday, June 27, 2025.
| Earnings Date | Jun 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ENDV has 1.21 billion shares outstanding.
| Current Share Class | 1.21B |
| Shares Outstanding | 1.21B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -77.91% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.47 |
| PB Ratio | -0.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.00
| Current Ratio | 0.00 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.15 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -144.27% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 11.44% |
| Revenue Per Employee | 255,723 |
| Profits Per Employee | -4.40M |
| Employee Count | 1 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.33% in the last 52 weeks. The beta is -1.97, so ENDV's price volatility has been lower than the market average.
| Beta (5Y) | -1.97 |
| 52-Week Price Change | -93.33% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 40.91 |
| Average Volume (20 Days) | 16,706,880 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, ENDV had revenue of 255,723 and -4.40 million in losses. Loss per share was -0.06.
| Revenue | 255,723 |
| Gross Profit | 246,034 |
| Operating Income | -2.62M |
| Pretax Income | -4.40M |
| Net Income | -4.40M |
| EBITDA | -1.97M |
| EBIT | -2.62M |
| Loss Per Share | -0.06 |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | 7.06M |
| Net Cash | -7.06M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -22.96M |
| Book Value Per Share | -0.07 |
| Working Capital | -23.66M |
Cash Flow
| Operating Cash Flow | -629,904 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 96.21% |
| Operating Margin | -1,023.16% |
| Pretax Margin | -1,722.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ENDV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -130.88% |
| Shareholder Yield | -130.88% |
| Earnings Yield | -3,650.01% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 20, 2019. It was a reverse split with a ratio of 0.001.
| Last Split Date | Dec 20, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.001 |
Scores
ENDV has an Altman Z-Score of -159.34 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -159.34 |
| Piotroski F-Score | 4 |